UUNIVERCELL BIOSOLUTIONS (UB) and STROMALAB are associated within the CARDIO-PREDICT project to develop functional human cardiomyocytes, derived from induced pluripotent stem cells (CSPi), intended for studies of efficacy and cardiotoxicity of pharmaceutical molecules. Such a model is highly anticipated by manufacturers in order to answer questions 1) about the safety and cost of drugs via the detection, from preclinical studies, of potentially human-specific toxic effects and 2) regulatory and ethical, related to the reduction of the use of animal models.